Similar articles

• Elective cyclosporine withdrawal in renal transplant recipients maintained on triple therapy.

  Keitel E, Bittar AE, Losekann A, Deboni L, Ceretta F, Goldani JC, Garcia VD. Keitel E, et al. Transplant Proc. 1992 Dec;24(6):2606-8. Transplant Proc. 1992. PMID: 1465881 No abstract available.
• Role of maintenance immunosuppression and methylprednisolone in OKT3-induced cytokine release.

  Peces R, Urra JM, Gorostidi M, López-Larrea C. Peces R, et al. Transplant Proc. 1992 Dec;24(6):2596-9. Transplant Proc. 1992. PMID: 1465877 No abstract available.
• Evidence for granulocyte activation by OKT3.

  Schmaldienst S, Böhmig G, Pohanka E, Kovarik J, Zlabinger GJ. Schmaldienst S, et al. Transplant Proc. 1992 Dec;24(6):2600-1. Transplant Proc. 1992. PMID: 1465878 No abstract available.
• [Cyclosporin in transplantation management--especially after kidney transplantation].

  Quellhorst E. Quellhorst E. Internist (Berl). 1996 Jan;37(1):88-90. Internist (Berl). 1996. PMID: 8837834 Review. German. No abstract available.
• Management of rejection, with reference to the kidney.

  Power D, d'Apice T. Power D, et al. Med J Aust. 1992 Nov 16;157(10):696-8. doi: 10.5694/j.1326-5377.1992.tb137439.x. Med J Aust. 1992. PMID: 1331723 Review. No abstract available.